Amicus Therapeutics is a biotechnology business based in the US. Amicus Therapeutics shares (FOLD) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $9.08 – an increase of 2.02% over the previous week. Amicus Therapeutics employs 499 staff and has a trailing 12-month revenue of around $528.3 million.
Offer ends 4/1/25. Customer must fund their Active invest account with at least $50 within 30 days of opening the account. Probability of customer receiving $2,000 is 0.028%. See full terms and conditions at https://www.sofi.com/greenintwoterms/.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – FOLD.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Amicus Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Amicus Therapeutics stock price (NASDAQ: FOLD)
Use our graph to track the performance of FOLD stocks over time.
Is it a good time to buy Amicus Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Amicus Therapeutics price performance over time
Historical closes compared with the close of $9.2 from 2025-03-19
1 week (2025-03-13)
4.43%
1 month (2025-02-21)
0.11%
3 months (2024-12-20)
-6.12%
6 months (2024-09-20)
-18.51%
1 year (2024-03-20)
-23.33%
2 years (2023-03-20)
-20.28%
3 years (2022-03-18)
10.07
5 years (2020-03-20)
7.35%
Is Amicus Therapeutics stock undervalued or overvalued?
Valuing Amicus Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amicus Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amicus Therapeutics's EBITDA
Amicus Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $42.6 million.
The EBITDA is a measure of a Amicus Therapeutics's overall financial performance and is widely used to measure a its profitability.
Amicus Therapeutics financials
Revenue TTM
$528.3 million
Operating margin TTM
10.67%
Gross profit TTM
$475.4 million
Return on assets TTM
2.72%
Return on equity TTM
-31.68%
Profit margin
-10.62%
Book value
$0.65
Market Capitalization
$2.8 billion
TTM: trailing 12 months
Amicus Therapeutics share dividends
We're not expecting Amicus Therapeutics to pay a dividend over the next 12 months.
Amicus Therapeutics share price volatility
Over the last 12 months, Amicus Therapeutics's shares have ranged in value from as little as $8.545 up to $12.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amicus Therapeutics's is 0.688. This would suggest that Amicus Therapeutics's shares are less volatile than average (for this exchange).
Amicus Therapeutics overview
Amicus Therapeutics, Inc. , a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. .
Frequently asked questions
null What percentage of Amicus Therapeutics is owned by insiders or institutions? Currently 0.826% of Amicus Therapeutics shares are held by insiders and 100.186% by institutions.How many people work for Amicus Therapeutics? Latest data suggests 499 work at Amicus Therapeutics.When does the fiscal year end for Amicus Therapeutics? Amicus Therapeutics's fiscal year ends in December.Where is Amicus Therapeutics based? Amicus Therapeutics's address is: 47 Hulfish Street, Princeton, NJ, United States, 08542What is Amicus Therapeutics's ISIN number? Amicus Therapeutics's international securities identification number is: US03152W1099What is Amicus Therapeutics's CUSIP number? Amicus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03152W109
A deep dive into the highlights and limitations of Robinhood.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
